Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.77+0.27 (+4.15%)
Close on Nov 18, 2026Market cap $67.96MP/E –Yield –
Atara Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Atara Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$50.94M. For fiscal 2025 it was -$50.94M. The highest annual figure on record is -$5.97M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$50.94M | – |
| FY2024 | Dec 31, 2024 | -$68.96M | – |
| FY2023 | Dec 31, 2023 | -$194.20M | – |
| FY2022 | Dec 31, 2022 | -$274.62M | – |
| FY2021 | Dec 31, 2021 | -$231.10M | – |
| FY2020 | Dec 31, 2020 | -$185.27M | – |
| FY2019 | Dec 31, 2019 | -$241.36M | – |
| FY2018 | Dec 31, 2018 | -$215.70M | – |
| FY2017 | Dec 31, 2017 | -$107.73M | – |
| FY2016 | Dec 31, 2016 | -$63.05M | – |
| FY2015 | Dec 31, 2015 | -$37.45M | – |
| FY2014 | Dec 31, 2014 | -$16.67M | – |
| FY2013 | Dec 31, 2013 | -$5.97M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$5.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.67M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$50.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$53.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$65.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$65.38M | – |
| Q1 FY2022 | Mar 31, 2022 | -$87.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$36.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$62.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$63.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$67.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.72M | – |
| Q3 FY2020 | Sep 30, 2020 | -$53.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$58.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$68.38M | – |
| Q4 FY2019 | Dec 31, 2019 | -$61.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$53.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$55.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$71.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$61.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$52.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$46.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$54.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$34.64M | – |
| Q3 FY2017 | Sep 30, 2017 | -$26.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -$23.44M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.16M | – |
| Q3 FY2016 | Sep 30, 2016 | -$15.97M | – |
See a number that looks wrong?